Aclaris Therapeutics (ACRS) Total Current Liabilities (2014 - 2026)

Aclaris Therapeutics' Total Current Liabilities history runs 13 years deep, the most recent figure standing at $27.4 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 27.22% year-over-year to $27.4 million; the TTM figure through Mar 2026 stood at $27.4 million (up 27.22% YoY), while the FY2025 annual figure was $28.6 million, down 9.34% from the prior year.
• Total Current Liabilities was $27.4 million for Q1 2026 at Aclaris Therapeutics, down from $28.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $31.6 million in Q4 2024 to a low of $15.7 million in Q2 2024.
• Historically, Total Current Liabilities has averaged $23.0 million across 5 years, with a median of $21.9 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities tumbled 31.31% in 2024, then soared 71.15% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $21.9 million in 2022, then jumped by 41.09% to $31.0 million in 2023, then rose by 2.08% to $31.6 million in 2024, then slipped by 9.34% to $28.6 million in 2025, then declined by 4.45% to $27.4 million in 2026.
• The last three Total Current Liabilities figures came in at $27.4 million (Q1 2026), $28.6 million (Q4 2025), and $25.6 million (Q3 2025), per Business Quant data.